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Abstract 
Ulixertinib (BVD-523) is a novel and selective reversible inhibitor of ERK1/ERK2. In xenograft studies it 
inhibited tumor growth in BRAF-mutant melanoma and colorectal xenografts as well as KRAS-mutant 
colorectal and pancreatic models. Ulixertinib is currently in Phase I clinical development for the treatment 
of advance solid tumors. The objective of the study is to assess the metabolic stability (in various pre-
clinical and human liver microsomes/hepatocytes), permeability, protein binding, CYP inhibition, CYP 
induction and CYP phenotyping of ulixertinib. We have also studied the oral and intravenous 
pharmacokinetics of ulixertinib in mice, rats and dogs. Ulixertinib was found to be moderately to highly 
stable in various liver microsomes/hepatocytes tested. It is a medium permeable (2.67 x 10
-6
 cm /sec) drug 
and a substrate for efflux (efflux ratio: 3.02) in Caco-2 model. Ulixertinib was highly bound to plasma 
proteins. CYPs involved in its limited metabolism and it is CYP inhibition IC50 ranged between 10-20 µM. 
Post oral administration ulixertinib exhibited early Tmax (0.50-0.75 h) in mice and rats indicating absorption 
was rapid, however in dogs Tmax attained at 2 h. The half-life (t½) of ulixertinib by intravenous and oral 
routes ranged between 1.0-2.5 h across the species. Clearance and volume of distribution by intravenous 
route for ulixertinib were found to be 6.24 mL/min/kg and 0.56 L/kg; 1.67 mL/min/kg and 0.36 L/kg and 
15.5 mL/min/kg and 1.61 L/kg in mice, rats and dogs, respectively. Absolute oral bioavailability in mice and 
rats was > 92 %, however in dogs it was 34 %. 
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Introduction 
The extracellular-signal-regulated kinases, ERK1 and ERK2 (ERK1/2), play a critical role in the 
RAS/RAF/MEK signaling pathway, that controls several fundamental cellular processes, driving 
proliferation, differentiation and cell survival [1]. RAS/RAF/MEK signaling pathway is frequently activated 
by mutations in upstream targets such as BRAF, RAS and receptor tyrosine kinases [2]. Most of the 
resistance mechanisms to BRAF and MEK inhibitors ultimately lead to increase in phosphorylation of 
ERK1/2 suggesting the importance of this node in the RAS/RAF/MEK pathway even in the resistance setting 
[3]. RAS activating mutations have been reported in about 90 % of pancreatic carcinomas, followed by 
colon carcinomas (50 %), lung cancers and myeloid leukemia cases (30 % each) [4]. Therefore, inhibition of 
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ERK1/2 offers a promising strategy to address both innate and acquired resistance to BRAF and MEK 
inhibitors in various solid tumors. Ulixertinib (BVD-523, VRT752271; Figure 1) is a first-in-class novel small 
molecule, which potently and selectively inhibits ERK1/2 kinases in a reversible, ATP-competitive fashion. 
Inhibition of ERK1/2 leads to proliferation inhibition (by decreasing the expression of VEGFA and VEGFR2 at 
mRNA and protein level), cell cycle arrest and apoptosis in lymphoma cell lines [5]. Ulixertinib inhibits 
tumor growth in vivo in BRAF-mutant melanoma and colorectal xenografts as well as in KRAS-mutant 
colorectal and pancreatic models [6]. In clinical studies, ulixertinib was well tolerated by patients with 
advanced solid tumors. In an oral Phase-I dose escalation study (having 9 doses) with an end point to 
determine the dose limited toxicities (DLT), maximum tolerated dose (MTD) along with pharmacokinetic 
profile and preliminary efficacy assessment it was administered in a dose range of 10-900 mg in a b.i.d 
regimen. Ulixertinib showed linear pharmacokinetics up to 600 mg (b.i.d), this was found to be MTD [7]. 
 
Figure 1. Structural representation of ulixertinib 
To date there is no publication on preclinical pharmacokinetics of ERK1/2 inhibitors, hence we felt that 
preliminary data on various in vitro ADME studies and in vivo pharmacokinetics in mice, rats and dogs of 
ulixertinib will help researchers in this field to provide the differentiating features in this class. This paper 
describes various in vitro experiments done to (a) assess the metabolic stability of ulixertinib in various 
preclinical species and human liver microsomes and hepatocytes (b) determine the permeability in Caco-2 
cells (c) determine the unbound fraction in preclinical species and human plasma (d) CYP inhibition (e) CYP 
induction and (f) CYP phenotyping of ulixertinib. Moreover, a series of in vivo experiments in Balb/C mice, 
Sprague Dawley rats and Beagle dogs were performed to characterize and understand pharmacokinetic 
parameters and absolute oral bioavailability of ulixertinib across the species. 
Materials and methods  
Materials 
Ulixertinib (purity >99 %) was purchased from MedKoo Biosciences, Inc., NC, USA. HPLC grade 
acetonitrile, formic acid and methanol were purchased from Rankem, Ranbaxy Fine Chemicals Limited, 
New Delhi, India. Preclinical species and human liver microsomes and hepatocytes were purchased from 
Life Technologies (Gibco®), Inchinnan, UK. Substrates and inhibitors of CYP isoforms like midazolam, 
quinidine, diclofenac, bufuralol, omeprazole, verapamil, rifampicin, warfarin, tolbutamide, phenacetin, 
ketoconazole, sulfaphenazole, nootkatone, furafylline and digoxin were purchased from Sigma-Aldrich 
Chemie GmbH, Steinheim, Germany. All other chemicals/reagents were of research grade and used 




R. Mullangi et al.   ADMET & DMPK 5(4) (2017) 212-223 
214  
In vitro studies 
Metabolic stability in liver microsomes 
Metabolic stability is defined as the percentage of parent compound lost over time in the presence of a 
metabolically active test system. The incubation mixtures consisted of liver microsomes (0.5 mg 
microsomal protein/mL), ulixertinib (1 μM) or positive control (verapamil, 1 μM). The reactions were 
initiated by adding 20 μL of 10 mM NADPH [8]. Reactions without NADPH (0 and 30 min) were also 
incubated to rule out non-NADPH metabolism or chemical instability in the incubation buffer [8]. All 
reactions were terminated using 200 μL of ice-cold acetonitrile containing internal standard (200 ng/mL of 
phenacetin) at 0, 5, 15 and 30 min. The vials were centrifuged at 3000 rpm (Eppendorf 5424R, Germany) 
for 15 min. The supernatants thus obtained were analyzed on LC-MS/MS to monitor the disappearance of 
ulixertinib.  
Metabolic stability in hepatocytes 
After checking the viability of cryopreserved hepatocytes, they were distributed 1 million viable cells 
per mL. An aliquot of 100 µL of thawed hepatocytes cell suspension was aliquoted into different vials 
labeled as 0, 30, 60, 120 and 180 min (mouse, rat, dog or human hepatocytes) and ulixertinib (3 μM). 
Imipramine or naloxone (3 μM) was used as a positive control [9]. The vials were pre-incubated in a 37 °C 
water bath for 5 min. All reactions were terminated using 200 μL of ice-cold acetonitrile containing internal 
standard (200 ng/mL of phenacetin) at specified time points. The vials (having reaction mixture terminated 
contents) were centrifuged at 3000 rpm (Eppendorf 5424R, Germany) for 15 min. The supernatants thus 
obtained were analyzed on LC-MS/MS to monitor the disappearance of ulixertinib. Clearance rate and half-
life were calculated using the obtained data. 
Caco-2 permeability 
Caco-2 human intestinal epithelial cells were plated in 24-Transwell® dual chamber plates (Millipore, 
Billerica, MA, USA) (cell density of 80,000 cells/cm2 on day-1). The permeability studies were conducted 
with the monolayers cultured for 21 to 22 days. The integrity of each Caco-2 cell monolayer was certified 
by trans epithelial electrical resistance (TEER) test (pre-experiment) and by determining the permeability of 
reference compound i.e., Lucifer yellow. Caco-2 cell monolayers with TEER values greater than 500 Ω cm2 
were considered for experimentation. Digoxin (5 µM) was used as a positive control for P-gp substrate 
[10]. The concentration of ulixertinib used in the assay was 10 µM. HBSS Buffer was used as the medium 
for the transport assay and the final concentration of DMSO in spiking solution was 0.05 %. The bi-
directional permeability study was initiated by adding an appropriate volume of HBSS buffer containing 
ulixertinib to respective apical and basolateral chambers (n=2) [11]. An aliquot of sample (100 µL) was 
taken from both chambers at 0 and 60 min of the incubation period and to this equal volume of 
acetonitrile with internal standard (200 ng/mL of phenacetin) was added, mixed gently and centrifuged at 
4000 rpm (Eppendorf 5424R, Germany) for 10 min. An aliquot of 100 µL was subsequently transferred to 
the auto-sampler and injected for analysis on LC-MS/MS. 
Plasma protein binding  
To evaluate the ability of ulixertinib to bind the plasma proteins, the most common approach of plasma 
protein binding using equilibrium dialysis was used [12]. Ulixertinib was tested at a final concentration of 3 
µM in mouse, rat and dog plasma. An aliquot of 150 μL plasma containing ulixertinib was added in first half 
(plasma side) of the well of 96-well micro-equilibrium dialysis device. An aliquot of 150 μL of 100 mM 
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sodium phosphate buffer pH 7.4 was added in the second half (buffer side) of the well of 96-well HT 
equilibrium dialysis device. The plate containing plasma and buffer was equilibrated at 37 ± 1 °C for 4.5 h, 
with constant shaking at 120 rpm on an orbital shaker. Samples were collected from respective halves after 
the completion of incubation time. The proteins were precipitated using organic solvents. The samples 
were subjected to centrifugation and the supernatants were analyzed analysis on LC-MS/MS. 
CYP inhibition 
CYP inhibition potential of ulixertinib was assessed in human liver microsomes [Life Technologies 
(Gibco®), Inchinnan, UK] against CYP3A4, 2D6, 1A2, 2C9 and 2C19 in the following sequential steps. 
Standard reaction mixture (final volume 300 μL) contained 66.7 M potassium phosphate buffer (pH 7.4), 
protein [0.1 (for CYP3A4), 0.25 (for CYP2D6), 0.5 mg/mL (for CYP1A2, 2C9 and 2C19)] and ulixertinib (at 
2.0, 10 and 20 µM, added as 0.9 µL DMSO solution with a final DMSO concentration of 0.1 %). The mixtures 
were pre-incubated at 37 ± 1 °C for 5 min. The reaction (in duplicate) was initiated by addition of 30 µL of 
NADPH (10 mM) [13]. Reaction was terminated at 10 min by adding 300 µL of ice cold acetonitrile with 
internal standard. The activity of liver microsomes was confirmed with positive controls i.e., monitoring the 
hydroxylation of midazolam, bufuralol, diclofenac and omeprazole for CYP3A4, 2D6, 2C9 and 2C19, 
respectively and deethylation of phenacetin for CYP1A2 (data not shown). The reaction mixtures (obtained 
from the above studies) were extracted, processed, analyzed on LC-MS/MS. 
rhCYP metabolism 
To evaluate the metabolism of ulixertinib, the most common approach of reaction phenotyping by using 
cDNA expressed enzyme system was used. Ulixertinib was incubated with a panel of individually-expressed 
recombinant human CYP enzymes (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4, purchased from Life 
Technologies (Gibco®), Inchinnan, UK expressed in baculovirus-infected insect cell membranes. The 
incubation mixture contained ulixertinib at a final concentration of 0.1 μM, expressed CYP enzyme 
(50 pmol/mL), phosphate buffer (66.7 mM, pH 7.4) in a total volume of 1 mL. The reaction was initiated by 
the addition of 20 µL of NADPH after pre-incubation of the aliquots (180 µL) marked 0, 5, 15, 30 and 60 
min followed by incubation at 37 ± 1 °C. The reaction was terminated by the addition of equal volumes of 
ice cold acetonitrile with internal standard (200 ng/mL of phenacetin). The samples were centrifuged at 
3000 rpm (Eppendorf 5424R, Germany) at 4 °C for 20 min to precipitate proteins. Supernatants were then 
transferred to clean vials and stored at -20 °C until analysis. Incubations without NADPH were used as 
negative controls. Control incubations using probe substrates for individual recombinant humans CYPs 
were included to check for appropriate incubation conditions and as positive control for activity [15]. The 
samples were analyzed on LC-MS/MS. Disappearance of ulixertinib was compared to that of control 
treatment (no CYP enzymes present) in order to assess the contribution of a given CYP in ulixertinib 
metabolism.  
In vivo studies 
Formulations 
For oral administration a suspension formulation was prepared using Tween-80 and 0.5 % methyl 
cellulose. Weighed amount of ulixertinib was taken into a mortar and grinded into a fine powder with the 
help of a pestle. To this Tween-80 was added drop wise to wet the entire powder. Then slowly 0.5 % 
methyl cellulose was added with constant stirring to get a uniform suspension. The final strength of the 
suspension formulation was 10 mg/mL and it was administered to animal species at 10 mL/kg body weight. 
For intravenous (i.v.) administration a solution formulation was used (prepared using 10 % DMSO, 10 % 
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Solutol:absolute ethyl alcohol (1:1, v/v) and 80 % normal saline). The volume of administration for 
intravenous was 10 mL/kg for mice and 2 mL/kg for rats and dogs. 
Animal experiments details 
Institutional Animal Ethical Committee (IAEC) of Jubilant Biosys (IAEC/JDC/2017/121) nominated by 
CPCSEA (Committee for the Purpose of Control and Supervision of Experiments on Animals) approved the 
rodents pharmacokinetic experiments. Male Sprague Dawley rats (~7-8 weeks old) and BalbC mice (~6-10 
weeks old) were purchased from Vivo Biotech, Hyderabad, India. Animals were quarantined in Jubilant 
Biosys Animal House for a period of 7 days with a 12:12 h light:dark cycles, had free access to rodent food 
(Altromin Spezialfutter GmbH & Co. KG., Im Seelenkamp 20, D-32791, Lage, Germany) and water ad 
libitum. For all the experimental work animals were kept for fasting (4 h for BalbC mice and 12 h for 
Sprague Dawley rats) and during this time they were allowed to take water ad libitum. Food was provided 
2 h post-dose and water was allowed ad libitum.  
IAEC of Palamur Biosciences, Telangana, India (1312/PO/RcBiBt/S/L/09/CPCSEA) approved studies 
conducted in dogs. Male Beagle dogs (~1.0-1.5 year old) were housed in Palamur Biosciences Private 
Limited animal house facility in a temperature (18-28 °C) and humidity (30-70 %) controlled room and fed 
with Pedigree standard pellet food and water ad libitum for one week before using for experimental 
purpose. For all the experimental work animals were kept for 12 h overnight fasting and during this time 
they were allowed to take water ad libitum. Food was provided 4 h post-dose and water was allowed ad 
libitum. 
Pharmacokinetic studies 
Oral bioavailability of ulixertinib was evaluated in male Balb/C mice, Sprague Dawley rats and Beagle 
dogs. Fasted mice (~4 h) and rats (overnight ~12 h) were divided into two groups (mice: 12/group; rats: 
4/group), however in cases of dogs (n=2; fasted for ~12 h overnight) same dogs were dose after one week 
wash-out period (cross over design). In each species Group-1 animals received ulixertinib through 
intravenous route at a dose of 1 mg/kg; whereas Group 2 received ulixertinib through oral gavage at 10 
mg/kg dose. Serial blood samples [100 µL in case of mice (sparse sampling; n=3 at each time point) and 
rats; 500 µL in dogs)] were collected from retro-orbital plexus at 0.12, 0.25, 0.5, 1, 2, 4, 8, and 24 h 
(intravenous administration) or at 0.25, 0.5, 1, 2, 4, 8, 10 and 24 h (oral administration) after drug 
administration. Blood samples were collected in tubes containing K2.EDTA as the anticoagulant and 
centrifuged for 5 min at 14000 rpm in a refrigerated centrifuge (Biofuge, Heraeus, Germany) maintained at 
4 °C for plasma separation and stored frozen at -80 ± 10 °C until analysis.  
Sample processing 
In vitro studies samples analysis 
A Shimadzu (Shimadzu, Kyoto, Japan) SIL series LC system equipped with a degasser (DGU-20A3), 
isopump (LC-20 AD) and column oven (CTO-10AS) along with an auto-sampler (SIL-HTc) was used to inject 
10 µL aliquots of the processed samples on a Atlantis C18 column (50 x 4.6 mm, 3 µm; Waters, Ireland, UK), 
which was maintained at 40 °C. The mobile phase system consisted of reservoir A (acetonitrile) and 
reservoir B (0.2 % formic acid in water) were run as per gradient program (0-0.1 min: 10 % A and 90 % B; 
0.1-2.8 min: 100 % A; 2.9-4.0 min 10 % A and 90 % B). A flow rate of 0.8 mL/min with a 50 % splitter was 
used throughout the analytical run. Quantitation was achieved by MS/MS detection in positive ion mode 
for ulixertinib using an API-4000 Q Trap mass spectrometer (MDS Sciex, Toronto, Canada) equipped with a 
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Turboionspray interface at 450 °C temperature and 5500 V ion spray voltage. The source parameters viz., 
curtain gas, GS1, GS2 and CAD were set at 30, 35, 40 and 6 psi. The compound parameters viz., 
declustering potential (DP), entrance potential (EP), collision energy (CE) and collision cell exit potential 
(CXP) were 81, 10, 49 and 15 V for ulixertinib and 80, 10, 29 and 14 V for the IS. Detection of the ions was 
performed in the multiple reaction monitoring (MRM) mode, monitoring the transition of the m/z 433 
precursor ion to the m/z 262 product ion for ulixertinib and m/z 180 precursor ion to the m/z 110 product 
ion for the IS. Quadrupole Q1 and Q3 were set on unit resolution. The dwell time was 150 msec. 
Plasma samples processing and analysis 
An aliquot of 50 µL plasma sample was precipitated with 200 µL of acetonitrile:methanol (1:1, v/v) 
enriched with internal standard (200 ng/mL of phenacetin) and centrifuged at 14,000 rpm for 5 min 
(Eppendorf 5424R, Germany) at 5 °C. Clear supernatant (125 µL) was transferred into vials and 5 µL of 
supernatant was injected onto LC-MS/MS system for analysis using a validated method [16]. The linearity 
range was 1.05-2096 ng/mL. In-study quality control (QC) samples, supplemented with concentrations of 
3.14, 1048 and 1747 ng/mL of ulixertinib, were analysed with the unknowns. Plasma samples showing high 
concentration above the high calibration standard were diluted with appropriate animal species blank 
plasma to bring the concentration within linearity range. 
For plasma samples analysis the criteria for acceptance of the analytical runs encompassed the 
following: (i) 67 % of the QC samples accuracy must be within 85-115 % of the nominal concentration (ii) 
not less than 50 % at each QC concentration level must meet the acceptance criteria. Following completion 
of the analysis both the linearity and quality control samples values were found to be within the accepted 
variable limits. 
Pharmacokinetic Analysis 
Pharmacokinetic parameters were calculated by a non-compartmental method using Phoenix 
WinNonlin 7.0 software (Pharsight, Mountain View, CA, USA). Absolute oral bioavailability (F) was 
calculated using the relationship, F = [Dose (i.v.) x AUC(0-)oral / Dose (oral) x AUC(0-)i.v.] x 100. 
Results  
In vitro studies 
Metabolic stability in liver microsomes 
Metabolic stability of ulixertinib in different species of liver microsomes is presented in Table 1. 
Ulixertinib was found to be moderately stable in mice and dog liver microsomes and highly stable rat and 
human liver microsomes.  
Metabolic stability in hepatocytes 
Hepatocyte stability of ulixertinib in different species is presented in Table 2. Ulixertinib was found to be 
highly stable in rat and human hepatocytes but moderately stable in mice and dog hepatocytes. The in vivo 
intrinsic clearance (Clint) was relatively low to moderate in rat and human hepatocytes but high in mice 
and dog hepatocytes. 
Caco-2 permeability 
Table 3 shows the rate of transport (Papp) of ulixertinib and digoxin from A → B and B → A along with 
efflux ratio values. The findings suggested that ulixertinib is a medium permeable compound and may be a 
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substrate of an active efflux transporter.  
 










Mice 44.5 36 19.3 27.7 
Rat 16.4 122 5.7 7.6 
Dog 35.5 52 13.3 9.1 
Human 12.8 142 9.8 5.4 
 










Mice 79 78 8.9 41.3 
Rat 27 410 1.7 7.1 
Dog 76  73 9.1 16.4 
Human 37  306 2.3 5.0 
 
Table 3.  Permeability data of ulixertinib in Caco-2 cell monolayers 
 









B  A A  B B  A A  B 
B  A/ 
A  B 
Ulixertinib 10 79 65 8.09  2.67  3.02 
Digoxin 5.0 98 75 10.5 1.00  10.5 
 
Plasma protein binding 
Ulixertinib had a very high binding in rat plasma followed by mouse and dog plasma with fraction 
unbound of 0.001, 0.003 and 0.050, respectively. The stability and recovery of ulixertinib in plasma was 
good across the species tested. 
CYP inhibition 
The predicted IC50 values of ulixertinib were determined for CYP-specific hydroxylation of midazolam, 
bufuralol, diclofenac and omeprazole for CYP 3A4, 2D6, 2C9 and 2C19, respectively and deethylation of 
CYP1A2. Ulixertinib did not show notable inhibition against these enzymes and the predicted IC50 values of 
ulixertinib were found to be ~10 and 20 µM for CYP 3A4 and 2D6, respectively indicating it is a weak 
inhibitor against these two CYPs. Furthermore, its inhibitory effect was much weaker against CYP1A2, 2C9 
and 2C19 as its IC50 was > 20 µM. Thus, when compared with known inhibitors, ulixertinib shows less 
significant inhibition of CYP enzyme activity in vitro (Table 4).  
CYP induction 
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Ulixertinib was tested at two different concentrations (1 and 10 µM). The readings suggested no or very 
less percent activation compared against rifampicin, a known CYP3A4 inducer. 
 
Table 4.  IC50 values for CYP450 inhibition by ulixertinib and other known CYP inhibitors 
 IC50 (µM) 
Inhibitor CYP3A4 CYP2D6 CYP2C9 CYP2C19 CYP1A2 
Ulixertinib ~10 ~20 >20 >20 >20 
Ketoconazole 0.08 NT NT NT NT 
Quinidine NT 0.12 NT NT NT 
Sulphaphenazole NT NT 0.72 NT NT 
Nootkatone NT NT NT 1.02 NT 
Furafylline NT NT NT NT 0.58 
 
rhCYP metabolism 
Data following incubations with different CYP isozymes (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4) 
considered in the panel suggested very minimal contribution of CYP1A2, 2C9, 2C19, 2D6 and 3A4 towards 
the metabolism of ulixertinib involving oxidation and dealkylation. This data is corroborating with the work 
reported by Germann et al [6]. 
Pharmacokinetic studies 
The profiles of plasma concentration for ulixertinib following single oral and intravenous administration 
to mice, rats and dogs are shown in Figure 2A and 2B, respectively. The estimates of pharmacokinetic 
parameters in these species are summarized in Table 5.  








Plasma concentration versus time profile











































Plasma concentration versus time profile




































Figure 2. Plasma concentration-time profiles of ulixertinib after (A) oral (10 mg/kg) and (B) intravenous (1 
mg/kg) administration to male Balb/C mice (mean  S.D, n = 12), Sprague Dawley rats (mean  S.D, n = 4) and 
Beagle dogs (mean, n = 2). 
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In the mice, plasma concentrations of ulixertinib decreased mono-exponentially manner after 1 mg/kg 
intravenous administration. The clearance was 6.24 mL/min/kg [7 % hepatic blood flow (HBF)]. The in vivo 
clearance was bit over predicted by the in vitro microsomes (~4-fold) and hepatocytes (~6-fold) scaled 
clearance. Ulixertinib had a high volume of distribution of 0.56 L/kg in mice, which is 38 times higher than 
that of total body water (TBW) of 0.015 L/kg [17]. The terminal t1/2 was found to be 1.04 h. Post oral 
administration maximum plasma concentrations (Cmax: 7768 ng/mL) attained at 0.5 h indicating rapid 
absorption from gastrointestinal tract. The terminal t1/2 (2.06 h) determined after oral administration was 
longer than that after intravenous administration (1.04 h), which may indicate multiple sites absorption. 
The AUC0- attained post oral dose was 24460 ng*h/mL. The oral bioavailability in mice at 10 mg/kg was 
92 % (Table 5).  
Table 5. Pharmacokinetic parameters of ulixertinib after intravenous and oral administration to mice, rats and dogs at 






















Intravenous 1.0 2672 1918 --- 1.04 6.24 0.56 --- 

























--- --- 97.7  
Beagle 
dogs 
Intravenous 1.0 1091  1033  --- 1.21  15.5  1.61  --- 
Oral 10 3687 1442 2.00 1.29 --- --- 33.8 
 
In the rats, plasma concentrations of ulixertinib decreased mono-exponentially manner after 1 mg/kg 
intravenous administration. The clearance was found to be 1.67 mL/min/kg (3 % of HBF), which is in good 
agreement with in vitro (microsomes and hepatocytes) scaled clearance. The volume of distribution (0.36 
L/kg) of ulixertinib in rat is approximated to TBW. The terminal t1/2 was found to be 2.52 h. In rats also post 
oral administration early Tmax of 0.75 h suggesting that ulixertinib has a rapid absorption from 
gastrointestinal tract. The AUC0- and Cmax attained post oral dose was 98421 ng*h/mL and 15026 ng/mL, 
respectively. The terminal t1/2 determined after oral administration is 2.02 h, which is comparable to 
intravenous route half-life. The oral bioavailability in rat at 10 mg/kg was 98 % (Table 5).   
In the dogs also plasma concentrations of ulixertinib decreased mono-exponentially manner after 1 
mg/kg intravenous administration. The clearance was 15.5 mL/min/kg (~50 % HBF). The in vivo clearance 
was in good agreement with in vitro (microsomes and hepatocytes) predicted scaled clearance. The 
apparent volume of distribution 1.61 L/kg of ulixertinib in dogs is approximated to TBW. The terminal t1/2 
was found to be 1.21 h. In dogs post oral administration, maximum plasma concentrations (1442 ng/mL) of 
ulixertinib observed at 2.00 h, indicating it is a delayed Tmax (when compared with Tmax value of rodents). 
The AUC0- was 3687 ng h/mL. The terminal t1/2 determined after oral administration was 1.29 h. The oral 
bioavailability in dogs at 10 mg/kg was 34 % (Table 5). 
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Discussion 
RAS/RAF/MEK signaling pathway is frequently activated in many cancers [2] and clinical efficacy of BRAF 
and MEK inhibitors confirms targeting RAS/RAF/MEK pathway has therapeutic potential and great promise 
[18]. Most of the resistance mechanisms to BRAF and MEK inhibitors ultimately lead to increase in 
phosphorylation of ERK1/2 [3]. Therefore, inhibition of ERK1/2 offers a promising strategy to address both 
innate and acquired resistance to BRAF and MEK inhibitors in various solid tumors. Ulixertinib is a novel 
compound, which selectively and potently inhibits ERK1/2 kinases in a reversible, ATP-competitive fashion. 
As a single-agent it inhibits tumor growth in vivo in BRAF-mutant melanoma and colorectal xenografts as 
well as in KRAS-mutant colorectal and pancreatic models [6]. In Phase-1 clinical studies, ulixertinib was well 
tolerated by patients with advanced solid tumors. Ulixertinib showed linear pharmacokinetics up to 600 mg 
(b.i.d), this was found to be MTD [7]. To the best of our knowledge there is no preclinical pharmacokinetic 
data reported for ERK1/2 inhibitors in the literature. Preclinical pharmacokinetics of a novel target class 
drug has great influence on the development and investigation of potential candidates for the further drug 
design, which necessitates a through exploration and understanding of pharmacokinetic disposition. This is 
important since in vivo pharmacokinetic behavior and pharmacokinetic-pharmacodynamic correlation act 
as surrogates for clinical effectiveness of potential drug candidates. In this paper we report the metabolic 
stability, permeability, protein binding, CYP inhibition, CYP induction, CYP phenotyping and 
pharmacokinetics in mice, rats and dogs for ulixertinib. 
The metabolic stability data suggested that ulixertinib is moderately to highly stable under in vitro 
conditions using liver microsomal and hepatocytes preparations of various pre-clinical species and humans. 
The Caco-2 cell monolayer transport assay is well established test system for estimating drug absorption 
[19]. This Caco-2 cell monolayer system generated Papp value in absorptive direction for ulixertinib was  
2.67 x 10-6 cm/sec, indicating it is a moderately permeable compound, however the Papp value in secretive 
direction appeared to much higher (8.09 x 10
-6
 cm/sec), suggesting involvement of efflux transporters in 
the Caco-2 monolayer. Our results indicate that ulixertinib weakly inhibits the major CYPs tested and IC50 
values are greater than 20 µM (for most of CYPs tested). Ulixertinib did not show propensity to induce 
CYP34. So, CYP inhibition or induction is likely to represent a clinically significant risk of drug-drug 
interactions. Ulixertinib oral absorption in mice and rats was not limited by efflux as bioavailability in these 
two species was > 92 %. However in dogs the oral bioavailability was 34 % and this may be due to high 
unbound concentrations (fu 0.05 in dog plasma vs 0.001 and 0.003 in mice and rat plasma, respectively) in 
plasma and extensive metabolism in dogs thus ulixertinib had relatively high plasma clearance. In addition, 
higher volume of distribution of mice indicates that ulixertinib is highly distributed in mice compared to 
rats and dogs. Ulixertinib demonstrated high plasma clearance in dogs compared to rats and mice, which is 
50, 3.0 and 7.0 % of HBF, respectively and was very much predicted by the in vitro experiment, indicating 
the difference in hepatic metabolism. 
Conclusions 
In conclusion, the preclinical data gathered in this work provided evidence that ulixertinib has excellent 
oral bioavailability in rodents and acceptable bioavailability in dogs, adequate metabolic stability and 
devoid of drug-drug interactions liability and different mechanism of action may provide differentiating 
features from other oncology compounds in this class. Overall, looking at the ulixertinib preclinical data 
presented by us and its current clinical data provide a good platform for researches to develop novel 
ERK1/2 inhibitors with potential benefit as a single or concomitant solid tumor therapy.  
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